Skip to main content

Table 5 Treatment and outcomes of EGPA patients with and without CNS involvement

From: Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China

  With CNS involvement (n = 19) Without CNS involvement (n = 91) P value
Treatment, n (%)    
 GCs 19 (100) 88 (96.7) 1.000
  MP pulse 9 (47.4) 22 (24.2) 0.041*
  CYC 18 (94.7) 80 (87.9) 0.688
  Rituximab 0 (0) 1 (1.1) 1.000
  Plasma exchange 1 (5.3) 0 (0) 0.173
  IVIG 3 (15.8) 11 (12.1) 0.706
Outcomes, n (%)    
 Complete remission 17 (89.5) 73 (80.2) 0.517
 Partial relief 0 (0) 12 (13.2) 0.122
 Death 2 (10.5) 6 (6.6) 0.625
  1. The categorical variables are expressed as frequencies and ratios, and are further compared by Chi-square analysis or Fisher’s exact test
  2. EGPA, Eosinophilic Granulomatosis with Polyangiitis; CNS, Central Nervous System; GCs, glucocorticoids (including pulse, high, medium, and low doses); MP, methylprednisolone; CYC, cyclophosphamide (including all kinds of doses); IVIG, Intravenous immunoglobulin; *P< 0.05
\